The U.S. Preventive Services Task Force recently finalized their recommendation that men ages 55 to 69 should speak with their health care providers about prostate cancer screening using the prostate-specific antigen, or PSA. We'll discuss the latest on the procedure, which has a significant problem with false positives. We discuss the latest on the procedure, which has a significant problem with false positives, and hear about developments in research on prostate cancer.
Dr. Paul Alpert, clinical professor, department of urology, UCSF Medical Center
Dr. Mark S. Litwin, professor of urology and public health and urology department chair, UCLA
New Evidence for the Benefit of Prostate-specific Antigen Screening: Data From 400,887 Kaiser Permanente Patients (Urology Journal)